Non-Melanoma Skin Cancers Coverage from Every Angle
Advertisement
Advertisement

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Study Results on Retifanlimab

Posted: Thursday, January 6, 2022

Shailender Bhatia, MD, of the University of Washington, discusses phase II findings from the POD1UM-201 trial, which suggest that retifanlimab, an anti–PD-1 monoclonal antibody, may be a potential new treatment option for patients with advanced or metastatic Merkel cell carcinoma. Its treatment schedule of once every 4 weeks without the need for premedications would be less burdensome for patients, Dr. Bhatia noted.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.